ArticleAnnals of medicine and surgery (2012)2025
Guillain-Barré Syndrome After Inactivated Poliovirus Vaccination: A Rare Clinical Case Report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and importance: Guillain-Barré syndrome is a type of immune-mediated acute polyradiculoneuritis that is typically preceded by an unspecified infection. Case presentation: A 6-year-old black male preliminary school student who was admitted to the paediatric ward with generalized body weakness comprising both lower and upper extremities (unable to move legs and hands as a usual motor movement), not walking alone without caregiver assistance, being unable to swallow food, blurred vision, tingling in the feet and hands, an irregular heartbeat, and severe muscular pain. The patient had quadriparesis, or muscle weakness, in all four limbs (both legs and arms). Motor examination revealed decreased muscle strength in all limbs, with a Medical Research Council score of 2/5 in the right arm of the upper extremities and 1/5 in the right leg of the lower extremities, and 1/5 in the left leg of the lower extremities and 2/5 in the left arm of the upper extremities. According to the clinical signs of Guillain-Barré syndrome, he received 400 mg/kg of intravenous immunoglobulin every day for 5 days. Clinical discussion: The immune response in Guillain-Barré syndrome damages either myelin (acute inflammatory demyelinating polyradiculoneuritis) or the axon (acute motor axonal neuropathy, as well as acute motor and sensory axonal neuritis). Conclusion: In this study, the patient was diagnosed with acute inflammatory demyelinating polyradiculoneuritis, a subtype of Guillain-Barré syndrome. Intravenous immunoglobulin (400 mg/kg per day for 5 days) was administered to him to combat the Guillain-Barré syndrome antibodies responsible for nerve damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.